Study of the Effect of Velaglucerase Alfa (VPRIV®) on Bone-related Pathology in Treatment-naïve Participants With Type 1 Gaucher Disease

NCT02574286 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

21

Enrollment

INDUSTRY

Sponsor class

Conditions

Gaucher Disease

Interventions

DRUG: Velaglucerase alfa
DIETARY_SUPPLEMENT: Vitamin D

Sponsor

Shire